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Abstract  18 
Practical relevance: Blood and blood products are increasingly available for practitioners to use in 19 
the management of haematological conditions and can be lifesaving and therapeutically useful for 20 
patients with anaemia and/or coagulopathies. It is important for feline health care that donors are 21 
selected appropriately, and transfusions of blood or blood products are given to recipients that will 22 
benefit from them. Complications can occur, but can be avoided with careful donor management, 23 
understanding of blood type compatibility, recipient selection and transfusion monitoring.  24 
Clinical challenges: Feline blood transfusion can be a lifesaving procedure but also detrimental to 25 
donor and recipient without precautions. Cats have naturally occurring alloantibodies to red cell 26 
antigens and severe transfusion reactions can occur with type-mismatched transfusions. Blood 27 
transfusions can also transmit infectious agents to the recipient, so donor testing is essential. Finally, 28 
donors must be in good health, sedated as appropriate and blood collected in a safe and sterile 29 
fashion to optimize the benefit to recipients. Transfusion reactions are possible and can be mild to 30 
severe in nature. Autologous and xenotransfusions may be considered in certain situations.  31 
Evidence base: These Guidelines have been created by the authors and The International Society of 32 
Feline Medicine (ISFM) based on available literature. They are aimed at general practitioners to 33 
provide a practical guide to blood typing, cross-matching, blood collection and administration.   34 
Introduction  35 
Although feline blood transfusions are infrequently performed in primary care veterinary practice, 36 
they can be lifesaving 1, 2.  Availability of donors has limited the utility of this technique, but with 37 
growth of blood banks providing access to feline blood, the procedure may become more routine. It 38 
is important that veterinary practitioners select appropriate recipients and donors (in-clinic or stored 39 
blood) and administer blood correctly and with monitoring to mitigate the risks. These guidelines are 40 
written to provide practical information for practitioners on blood types and cross-matching, 41 
indications for transfusion, donor management, recipient preparation and monitoring and potential 42 
complications.   43 
 44 
Feline blood types  45 
Alloantigens 46 
Blood types arise due to the presence of genetically determined antigenic markers on the surface of 47 
red blood cells (RBCs). Blood type antigens are alloantigens as they exist in alternative (allelic) forms 48 
in different cats and can induce an immune response when one blood type is transferred to a cat that 49 
lacks it. One blood group system, the AB system, has been extensively defined in cats. Within the AB 50 
blood group system there are three blood type phenotypes, namely type A, type B and type AB: 51 
• Blood type A is common – N-glycolylneuraminic acid is the alloantigen on the RBC surface 52 
• Blood type B is less common, but common in some pedigree breeds e.g. British Shorthair, Birman, 53 
Devon Rex – N-acetylneuraminic acid is the alloantigen on the RBC surface 54 
• Blood type AB is rare – N-glycolylneuraminic acid and N-acetylneuraminic acid are the alloantigens 55 
on the RBC surface. 56 
 57 
Blood type prevalence varies geographically (see Table 1). Type A is the most common 58 
worldwide and in some breeds 100% of cats are believed to be type A (e.g. Siamese 3). The 59 
prevalence of type B is much lower than type A but it has been reported to be as high as 36% 60 
in non-pedigrees in Australia 4 and some breeds can contain high numbers of type B cats 61 
(especially the British Shorthair). Type AB is less common. Blood typing is essential to avoid 62 
what can be fatal transfusion reactions.   63 
 64 
Table 1: Blood types reported in different geographic locations in different breeds of cat in published 65 
studies. 66 
Country source of 
data (reference) 
Breed No. of 
cats 
Type A % Type B % Type AB % 
UK 5 
 
Non-pedigree 139 87.1 7.9 5.0 
British shorthair 121 39.7 58.7 1.6 
Birman 24 62.5 29.2 8.3 
Persian 17 88.2 11.8 0 
Other pedigrees 45 77.8 6.7 15.5 
UK 3 
 
Non-pedigree 105 67.6 30.5 1.9 
Siamese 13 100.0 0 0 
Other pedigrees 38 76.3 21.1 2.6 
UK 6 Bengal 100 100.0 0 0 
Denmark 7 
 
Non-pedigree 105 98.1 1.9 0 
Persian 56 96.4 3.6 0 
British shorthair 30 66.7 33.3 0 
Abyssinian 20 100 0 0 
Other pedigrees 33 90.9 9.1 0 
Australia 4 
 
Non-pedigree 355 62 36 1.6 
Siamese 12 100 0 0 
Country source of 
data (reference) 
Breed No. of 
cats 
Type A % Type B % Type AB % 
Devon Rex 70 45 54 1.4 
British shorthair 8 38 62 0 
New Zealand 8 Non-pedigree 245 70.6 13.9 0.8 
France 9 
 
Non-pedigree 320 83.8 14.4 1.9 
Pedigree 37 89.2 10.8 0 
Central Italy 10 Non-pedigree 483 89.8 7 3.1 
North Italy 11 Non-pedigree 233 91.0 5.2 3.8 1 
South Italy 11 Non-pedigree 215 77.2 12.1 10.7 




In contrast to dogs, cats can possess naturally occurring alloantibodies against the ‘foreign’ (non-self) 70 
alloantigen that they are lacking. These alloantibodies will recognise the alloantigens of another cat. 71 
Kittens develop these antibodies at 6-8 weeks of age. In the UK, for example, over 70% of type A cats 72 
have anti-B alloantibodies 13, which are mostly present at low concentrations, whilst all type B cats 73 
have anti-A alloantibodies, often present in high concentrations. In a report from the USA all type A 74 
cats had anti-B alloantibodies 14. Type AB cats never have alloantibodies to either type A or type B 75 
antigens. The reaction between the blood type alloantigens and any existing alloantibodies is 76 
observed during cross-matching donor and recipient blood.  77 
 78 
Alloantibodies are responsible for potentially fatal feline blood transfusion reactions that can arise 79 
when cats undergo their first blood transfusion, as they are already present in the cat’s circulation, 80 
ready to destroy RBCs of a different blood type phenotype. These alloantibodies are also responsible 81 
for neonatal isoerythrolysis 15, 16, a cause of neonatal death. The severity of a blood transfusion 82 
reaction also depends on the quantity (i.e. higher titres or concentrations worse) and nature (e.g. 83 
strongly agglutinating) of any alloantibodies present in the recipient (or donor). 84 
 85 
Donor and recipient cats must always be blood typed before transfusions. Type-compatible blood 86 
should be administered, i.e type A blood is given to type A cats, type B blood to type B cats, and 87 
type AB blood to type AB cats if possible. For type AB cats, if type AB blood is not available, type A 88 
blood (or ideally just the type A RBCs following separation) may be given  89 
 90 
BOX OUT START 91 
Blood Typing (Phenotyping) 92 
• Blood typing can be performed by submitting anticoagulated blood to a commercial laboratory or 93 
by using an in-clinic test kit. 94 
• Different kits are available for in-clinic feline blood typing; examples useful for general 95 
practitioners include RapidVet-H cards (DMS Laboratories Inc, Flemington, NJ, USA) based on 96 
agglutination (Figure 1a and Figure 1b) 17, RapidVet-H immunochromatographic (IC) tests (DMS 97 
Laboratories) (Figure 1c) and the QuickTest A+B (Alvedia, Limonest, France) (Figure 1d to Figure 98 
1h) 17, also based on IC methodology. The Lab.Test A+B (Alvedia) is similar to the QuickTest A+B 99 
but can be run on multiple (up to 20) samples and requires a microplate, pipette and test tube to 100 
be provided by the user. A gel tube in-clinic blood typing kit is also available (Rapid Vet-H Gel, DMS 101 
Laboratories Inc.) that relies on agglutination; this method includes a step that requires use of a 102 
centrifuge.  103 
• One study 18 found that the in-clinic QuickTest A+B performed slightly better than the RapidVet-H 104 
card test, and may be more reliable in cats with autoagglutination, but the new RapidVet-H IC test 105 
also appears to be reliable 19. A more recent publication, focusing on the Lab.Test A+B found it to 106 
outperform the RapidVet-H cards 20. The study also confirmed that the QuickTest A+B performed 107 
well on blood that had been stored in the fridge and at room temperature.  A recent study 21 108 
confirmed that the Lab.Test A+B was very reliable, performing as well as flow cytometry in the 109 
blood type phenotyping of a sample of 49 cats (34 A, 13 B and two AB). 110 
• The QuickTest A+B is a migration IC methodology test strip cartridge (Figure 1d to Figure 1h) that 111 
uses monoclonal antibodies (further details not given) to differentiate the blood antigens, 112 
whereas the RapidVet-H cards use a murine monoclonal antibody as the anti-A reagent and a 113 
lectin from Triticum vulgaris as the anti-B reagent. These different reagents may explain why the 114 
RapidVet-H cards wrongly describe some blood types, as one study 20 showed that the cards were 115 
found to sometimes mistype blood type AB cats as type B and occasionally blood type A cats as 116 
type AB.  117 
• An automated method for blood typing is available (QuickVet® Feline Blood Typing Test™), for use 118 
with the QuickVet® Analyzer (Zoetic ApS, Denmark). The QuickVet® Diagnostic System consists of 119 
an analyzer and single use disposable test cartridges based on capillary driven microfluidic 120 
technology.  121 
• If a sample to be blood typed is from a cat with severe anaemia (packed cell volume [PCV] <14%), 122 
the RBCs can be concentrated by centrifugation of the blood (2-3 mins, remove some of the 123 
plasma supernatant and resuspend the remaining RBCs in the remaining plasma supernatant) to 124 
get a higher concentration of RBCs, and repeat the test; this can be useful if insufficient RBCs reach 125 
the top of the test strip due to the low number present in a very anaemic sample. In a similar way, 126 
if agglutination of the sample precludes movement of the RBCs along the strip, the RBCs can be 127 
washed in phosphate buffered saline and the test repeated. 128 
• One study 18 found that some feline leukaemia virus (FeLV) infected anaemic cats were mistyped 129 
using multiple blood typing methods.  130 
• Cats with less common blood types (type AB and type B) may be mistyped by commercially 131 
available blood typing in-clinic methods and results should ideally be confirmed at an external 132 
laboratory by a method that uses antibody testing or genetic screening. However, a ‘back typing’ 133 
technique for antibody screening can be used in-clinic where type B is suspected: EDTA blood from 134 
the suspected type B cat is centrifuged at 1000 g for two minutes; 30 µl plasma is removed and 135 
mixed with 15 µl EDTA blood collected from a known type A cat on a glass microscope slide and 136 
observed for agglutination; if positive this confirms the B blood type, as the plasma of the type B 137 
cat contains alloantibodies that agglutinate the type A RBCs.  138 
BOX OUT END 139 
 140 
Non-AB feline blood groups 141 
Evidence published in 2007 suggested that other, non-AB, blood group systems existed in cats because 142 
blood transfusion reactions have occurred in cats given AB-matched blood transfusions. A study from 143 
the USA 22 reported the absence of a novel feline RBC antigen named Mik in three of 65 type A cats 144 
tested, in association with the presence of naturally occurring anti-Mik alloantibodies, which mediated 145 
a clinically significant transfusion reaction despite the blood donor and recipient cat being AB-146 
matched.  However, one study in UK cats 23, and another in German cats 24, found no evidence of anti-147 
Mik alloantibodies in the cats sampled in those studies, as no positive cross-matches between AB-148 
matched blood samples were found in transfusion naïve cats. Other studies 21, 25, 26 have, however, 149 
documented the presence of positive cross-matches between AB-matched blood samples, suggesting 150 
the presence of non-AB blood group systems, although the clinical significance of these is not always 151 
clear and tests for the Mik and other RBC antigens are not available commercially. In the most recent 152 
study 27, type A cats were evaluated for naturally occurring non-AB alloantibodies by cross-matching 153 
and at least 7% of the type A cats had incompatible cross-matching, documenting the presence of 154 
naturally occurring alloantibodies. Five distinct RBC antigens were hypothesized to be present outside 155 
of the AB blood group system and one of these was thought to correspond to the previously described 156 
Mik antigen.   157 
 158 
Cross-matching 159 
Cross-matching can be performed in-clinic or at an external laboratory; the latter is ideal as the test 160 
is complex and takes time but obviously this results in a delay in obtaining results. In-clinic cross-161 
matching kits are available. Based on all existing studies, the clinical effectiveness and need of cross-162 
matching before a first transfusion remains controversial, however, given that transfusion-naive cats 163 
may have incompatible major cross-matches, cross-matching, as well as blood typing, is 164 
recommended by some before each transfusion where possible in cats 27-29, although others have 165 
acknowledged that the strength of evidence for this is weak 30. A recent Australian study 31, 166 
questioning primarily general practitioner vets, reported that compatibility testing, including cross-167 
matching, before feline blood transfusions was commonly performed; cross-matching alone in 26%, 168 
blood typing alone in 27.6% and both in 34.1% of respondents.  169 
 170 
In emergency situations cross-matching may not be possible. However, it is strongly recommended 171 
that cross-matching is performed before a transfusion when the recipient has an unknown 172 
transfusion history or has had a previous transfusion reaction or has received a transfusion two or 173 
more days previously. The two day timeline stipulated is because incompatibilities have been 174 
identified by major cross-match testing as early as two days after a first whole blood cross-match 175 
compatible transfusion 24.  176 
 177 
BOX OUT START 178 
How to perform in-clinic cross-matching 179 
Cross-match methodology 180 
• 1 ml EDTA blood tube and a 1 ml serum (plain) tube obtained from each of the donor & recipient. 181 
Label tubes. 182 
• Centrifuge (3,000 rpm for 5 minutes) & separate plasma & serum from RBCs in both tubes. Discard 183 
the plasma if not required for other diagnostic investigations. Store serum in a separate tube & 184 
label. 185 
• Wash EDTA RBCs - add 2-3 mls of normal saline solution to the RBCs, mix gently & centrifuge 186 
(3,400 rpm for 1 minute) & remove the supernatant saline. Repeat twice.  187 
• After the 3rd wash, decant the supernatant & resuspend the RBCs with saline to give a 4% RBC 188 
suspension (0.2 mls RBCs with 4.8 mls saline). 189 
• Label four tubes & place the following into each:- 190 
Major cross-match  1 drop recipient serum & one drop donor RBC suspension 191 
Minor cross-match   1 drop donor serum & one drop recipient RBC suspension 192 
Recipient control  1 drop recipient serum & one drop recipient RBC suspension 193 
Donor control (optional) 1 drop donor serum & one drop donor RBC suspension 194 
• Incubate the tubes for 15 minutes at 37oC 195 
• Centrifuge the tubes for 15 seconds (3,400 rpm)  196 
• Read the tubes macroscopically and microscopically: 197 
Macroscopic cross-match reading  198 
In a compatible reaction there should be no clumping nor haemolysis nor agglutination present; when 199 
the tubes are gently rolled and rotated, RBCs should be able to float off freely from the centrifuged 200 
“pellet” of RBCs. The supernatant should be free of haemolysis (Figure 2).  201 
Microscopic cross-match reading  202 
A drop of the RBC/serum mixture from the tubes is placed on a microscope slide, cover slipped & 203 
viewed microscopically (within 60s of placing the blood on a microscope slide). The RBCs should be 204 
visible as individual cells & not in clumps. Rouleaux formation, where RBCs stick together as stacks of 205 
coins, can look macroscopically like agglutination but rouleaux formation (Figure 3a) can be 206 
differentiated from agglutination (Figure 3b) on microscopic examination.  Rouleaux formation is not 207 
a clinical concern but agglutination indicates an incompatible cross-match reaction. 208 
 209 
NB. Others have modified the above protocol to use plasma, rather than serum (as both can be used 210 
for cross-matching 32), along with a 3-5% suspension of RBCs in phosphate buffered saline (rather than 211 
saline), and to not perform the donor control but just the recipient control test 24. The study describing 212 
this modified method also reported that cross-matching could be done with as little as 250 µl (0.25 213 
mls) of blood, which is encouraging as minimising the amount of blood taken from anaemic cats is 214 
important.  215 
 216 
How to perform routine in-clinic cross-matching using kits 217 
In-clinic cross-match kits are available such as the RapidVet-H Major and Minor Cross-match kits (DMS 218 
Laboratories), which use serum, and the QuickTest XM EmMatest test or Lab.Test XM (both Alvedia), 219 
which use plasma. All kits can be used to perform both the major and minor cross-matches. A feline 220 
Gel.Test (Alvedia), which uses plasma, is also available for cross-matching, but this requires the 221 
mandatory use of a specific centrifuge. With all such kits, instructions should be carefully followed, 222 
but studies have yielded variable results with different methods and it is difficult to compare results 223 
27.  224 
BOX OUT END 225 
 226 
BOX OUT START 227 
How to perform emergency cross-matching 228 
If cross-matching is required in an emergency, the following method can be used which omits the 229 
washing of RBCs described above: 230 
• EDTA is collected from donor and recipient then centrifuged to separate plasma and RBCs  231 
• Major cross-match: 2 drops of recipient plasma and 1 drop of donor RBCs (so ~ major cross-232 
match) are then placed on a glass microscope slide and the slide examined microscopically for 233 
agglutination between 1 and 5 minutes, as described above. Agglutination must be differentiated 234 
from rouleaux formation microscopically as described above for routine cross-matching 235 
• Controls should also be performed using recipient plasma and RBCs and, if possible, donor plasma 236 
and RBCs, and examined microscopically 237 
• Note that drying out of blood on the slide can result in rouleaux formation but this takes > 5 238 
minutes to occur  239 
BOX OUT END 240 
 241 
Selecting a donor  242 
Infectious disease screening 243 
Risks from transfusion include the transmission of infectious agents from donor to recipient, which 244 
can be avoided largely through donor selection and screening. Such a process must vary between 245 
countries/regions and practices and will depend on locally endemic diseases, the practicalities in 246 
selecting donors that do not carry them and the cost/availability of screening compared to the risk of 247 
not having any available blood. 248 
 249 
In addition to the considerations above, individual donor factors such as indoor/outdoor status, 250 
ectoparasite control and time of last testing will influence the likelihood of infectious agent presence. 251 
These will in turn determine which agents should be screened for, the most appropriate methodology 252 
and also the required frequency, which may be deemed to be annually, or at the time of every blood 253 
donation if there is a high risk of novel exposure or intermittent circulation of a pathogen 33,34.  254 
 255 
Core infectious agents to test blood donors for 256 
Haemotropic Mycoplasmas  257 
The pathogenic Mycoplasma haemofelis can be transmitted by blood products, although it appears to 258 
be inactivated during storage of whole blood for one week 35. Blood smear evaluation is insensitive 259 
for diagnosis and also lacks specificity and thus the diagnostic test of choice for screening blood donors 260 
is PCR. PCR testing for ‘Candidatus Mycoplasma haemominutum’ (which may survive for a week in 261 
stored blood 35) and ‘Candidatus Mycoplasma turicensis’ can also be considered, but as these agents 262 
are of lower pathogenicity 36, donors may not be excluded if positive for these organisms if the donor 263 
pool is very limited.  Ideally, however, cats should be negative for these agents too. 264 
 265 
Bartonella spp. 266 
Numerous Bartonella species can be present in the blood of cats and have been associated with 267 
several clinical conditions 37. Bartonella henselae has been shown to survive in stored blood 38. Donors 268 
should ideally be serology and PCR negative for Bartonella spp. but seropositivity may be common in 269 
endemic areas and sensitive testing methods are not always readily available. Seropositive cats may 270 
have intermittent bacteraemia 39 but can be considered for donation if PCR negative. 271 
 272 
Feline leukaemia virus/feline immunodeficiency virus (FIV) 273 
Both FeLV and FIV can be transmitted by blood transfusion and thus donor cats need to be negative 274 
for both of these agents 40. Antigen tests for FeLV are commonly available, such as ELISA or IC in-clinic 275 
tests, but proviral DNA testing (by PCR) should be performed, if at all possible, as transmission of FeLV 276 
infection via blood transfusion has been documented by FeLV provirus positive, antigen negative 277 
blood (e.g. PCR positive, ELISA negative) 41. Antibody tests for FIV are commonly available as ELISA or 278 
IC in-clinic tests too and cats should be negative for FIV antibody before being used as donors. 279 
Although certain FIV antibody tests may be able to differentiate true FIV infected cats from those cats 280 
that have been vaccinated for FIV (in those countries where FIV vaccination is, or has been, available 281 
for use in cats), it is recommended that only FIV antibody negative cats are used as blood donors due 282 
to the potential for confusion in interpretation of test results 42. 283 
 284 
Additional agents to consider testing blood donor cats for 285 
Anaplasma spp. 286 
Anaplasma phagocytophilum can cause illness in cats, can be transmitted by blood inoculation, and 287 
exist as a persistent infection 43, 44. Donor cats with potential tick exposure (particularly Ixodes ricinus) 288 
from endemic areas should ideally be screened by serology and PCR, if available. Seropositive, PCR-289 
negative cats may be used in endemic regions if no other suitable donor can be identified. Infection 290 
with Anaplasma platys has been documented in cats 43 and so cats living in areas endemic to 291 
Rhipicephalus spp. ticks should be screened for this agent by PCR. 292 
 293 
Cytauxzoon felis, Babesia felis, Ehrlichia canis, Leishmania infantum and Neorickettsia risticii 294 
These are all vector-borne agents43-49, which may be transmittable by blood products. Although pre‐295 
donation physical examination and blood smear examination should minimize transmission risk, the 296 
optimal standard would be to have cats negative by PCR, if available, for these agents in blood donor 297 
cats living in endemic areas. 298 
 299 
Other infectious agents 300 
Screening for coronavirus, Rickettsia felis and Toxoplasma gondii is not recommended for donor cats. 301 
Transmission of these agents by blood products has not been documented.   302 
 303 
Donor characteristics 304 
Donors should be healthy, between one and eight years old and with a lean body weight above 305 
4.5kg. They should be of calm temperament and easy to handle to reduce sedation requirements. 306 
They should be current with all applicable vaccinations and parasite control and ideally live indoors 307 
without recent introduction of other cats to the household, to reduce their exposure to infections. 308 
No other recent medications should have been given and they should never have received a 309 
transfusion nor be currently pregnant. Cats that have previously had a litter may still be donors. 310 
Annual health screening of potential blood donors, including haematology and serum biochemistry 311 
profiles, is recommended. In addition, a complete history and physical examination, as well as 312 
determination of PCV or haemoglobin concentration, should be completed before each blood 313 
collection.   314 
 315 
Occult cardiomyopathy is excluded with echocardiography by some clinicians prior to allowing cats 316 
to join a donor program, given that up to 30% of cats with cardiac disease will not have a murmur 50. 317 
However, others would omit echocardiography and exclude cats with murmurs, gallops or 318 
arrythmias from donation, or perform quantitative NT-proBNP serum testing, which has been shown 319 
to reliably discriminate normal cats from those with occult cardiomyopathy 51.  320 
 321 
BOX OUT START 322 
Donor selection criteria 323 
• Between one and eight years of age 324 
• Lean body weight above 4.5kg 325 
• Calm temperament 326 
• Up to date with relevant vaccination, worming and ectoparasite treatments 327 
• No current medications 328 
• Ideally living indoors 329 
• No history of having received a transfusion 330 
• Annual haematology and serum biochemistry screening within reference intervals 331 
• FeLV antigen and FIV antibody testing negative (can be done in-clinic) and FeLV provirus PCR 332 
negative 333 
• Haemotropic mycoplasma & Bartonella spp. PCR testing negative 334 
• Negative for vector borne pathogens in endemic areas  335 
BOX OUT END 336 
 337 
Indications for blood transfusion 338 
Due to restrictions on storage of animal blood, most cats in the UK and in Europe in need of a blood 339 
transfusion will receive fresh whole blood (FWB), which contains all of the blood components: RBCs, 340 
platelets, coagulation factors, and plasma proteins. However, in countries where blood storage is 341 
available, feline FWB donations are processed into packed red blood cells (pRBCs) and fresh-frozen 342 
plasma (FFP) components. The use of these blood components has many advantages including 343 
extending resources, allowing specific replacement therapy, and potentially reducing the number of 344 
transfusion reactions.    345 
 346 
RBC products 347 
Red blood cell products, namely FWB and pRBCs, increase the oxygen-carrying capacity of the blood 348 
and thereby improve oxygen delivery to tissues. While FWB and pRBC transfusions can be used 349 
interchangeably in most anaemic cats, administration of pRBCs would be preferable to FWB to 350 
those, for example, with underlying cardiac disease to help avoid circulatory overload, and 351 
depending on the cause of the anaemia (e.g. if due to haemolysis rather than blood loss). The 352 
decision to administer a RBC product transfusion is frequently based on measurement of the cat’s 353 
PCV, haematocrit, or haemoglobin concentration. However, a “transfusion trigger” or threshold PCV 354 
below which a RBC transfusion is administered has not been clearly defined in human or veterinary 355 
medicine, and accompanying clinical signs are very important to consider in deciding if a transfusion 356 
should be considered. In two recent studies involving RBC transfusions in more than 265 cats, the 357 
pre-transfusion PCV was 15% (median value 25) and 17% (mean value 26), with a range of 5-40%. In 358 
some cats with peracute blood loss and hypovolaemia, RBC transfusions may be indicated even 359 
though their PCV is normal. These patients will predictably develop a low PCV following fluid 360 
resuscitation with asanguineous fluids.  361 
 362 
BOX OUT START 363 
The decision to transfuse RBC products is based on several factors in addition to PCV, including the 364 
onset of anaemia (if acute in nature, there may be more of a need compared to chronic onset 365 
anaemia), presence of ongoing RBC losses and, most importantly, the clinical signs of the patient. 366 
Tachycardia, bradycardia, bounding peripheral pulses, collapse, lethargy, and weakness are all signs 367 
that should prompt consideration of RBC transfusion.  368 
BOX OUT END 369 
 370 
In approximately 5-25% of cats, ineffective erythropoiesis and blood loss are the most common 371 
general causes of anaemia reported in cats receiving RBC transfusions, with haemolysis noted less 372 
frequently 25, 26, 29. Underlying conditions frequently associated with development of non-373 
regenerative anaemia in cats, and the potential need for a RBC transfusion, include chronic kidney 374 
disease, lymphoma, systemic inflammatory disease, infectious diseases, and bone marrow disorders 375 
52 and chronic unspecified diseases 29. An often-overlooked factor contributing to development of 376 
anaemia in hospitalized critically ill cats is repeated phlebotomy for blood sampling, with 74% of 377 
non-anaemic cats developing anaemia during an ICU stay in one study 53. In this study cats that 378 
required a pRBC transfusion had significantly more daily blood samples taken (median 3, range 1–6) 379 
than cats that did not require a transfusion (median 2, range 1–4).      380 
 381 
Plasma products 382 
Plasma separated from RBCs within eight hours of blood collection is referred to as fresh plasma, but 383 
in countries where stored veterinary blood products are available, fresh plasma is more often frozen 384 
after preparation and stored (-20 to -30°C) for up to one year; this type of plasma is referred to as 385 
fresh-frozen plasma (FFP). Fresh plasma and FFP contain haemostatic proteins (coagulation factors, 386 
von Willebrand factor, anticoagulant proteins, and fibrinolysins), albumin and immunoglobulins. The 387 
main indication for use of fresh plasma or FFP is bleeding due to inherited or acquired 388 
coagulopathies, but its use has also been reported in cats with hypotension, liver disease, neoplasia 389 
and sepsis 54. Although the benefit of prophylactic administration of plasma to cats with a 390 
coagulopathy (but not showing clinical signs of bleeding) undergoing an invasive procedure is 391 
unclear, it was reported to be the main reason for FFP transfusions in cats in another study 55. 392 
Anticoagulant rodenticide toxicity is uncommon in cats compared to dogs, but may occur after 393 
consumption of poisoned prey, and FFP as well as FWB may be included in the treatment protocol 55-394 
57.  395 
Hereditary haemostatic disorders are diagnosed infrequently in cats. There are two case reports of 396 
type 3 von Willebrand disease (VWD) 58, 59 and sporadic reports of haemophilia A and B (55, 60, 61) 397 
causing bleeding in cats. Plasma would be appropriate to provide replacement of von Willebrand 398 
factor in cats with VWD or factor VIII or IX in cats with haemophilia A or B, respectively, experiencing 399 
bleeding, though FWB would be an alternative if fresh plasma or FPP was not available or the cat 400 
was also anaemic. 401 
 402 
The effect of plasma on colloid osmotic pressure is less than that of synthetic colloids, and the use of 403 
plasma for volume expansion is not recommended 62. 404 
 405 
Platelet products 406 
Due to technical challenges associated with preparing platelet-rich plasma from a small volume 407 
feline FWB unit, cats in need of a platelet transfusion generally are administered FWB, although this 408 
will not provide adequate platelets to correct thrombocytopenia. There are few indications for 409 
platelet transfusions in cats, but include uncontrolled or life-threatening haemorrhage (e.g. 410 
pulmonary haemorrhage) with thrombocytopenia or thrombopathia, and possibly massive 411 
transfusion (rare but is when a high number of pRBCs have been given, which can cause by a 412 
dilutional effect on the recipient's clotting factors and platelets). While platelet disorders are 413 
uncommon in cats, primary immune-mediated thrombocytopenia can lead to severe blood loss 414 
anaemia, which can be managed with FWB transfusions 63. Cats with bleeding secondary to a 415 
thrombopathia typically require administration of functional platelets (for practical reasons in the 416 
form of FWB) to control bleeding 64.  417 
 418 
Xenotransfusion  419 
Xenotransfusion is defined as the transfer of blood from one species to another. Successful 420 
administration of whole blood or pRBCs from dogs to cats has been documented and can be 421 
performed if absolutely necessary and only as a single, one-off transfusion 65, 66. In some 422 
circumstances, dog blood may be more readily available than cat blood, and available in larger 423 
volumes, leading to its occasional use 31. Potential indications for xenotransfusion include previous 424 
transfusion reaction to feline blood products, insufficient time to blood type the recipient, non‐425 
availability of suitable feline blood products in sufficient quantities or financial constraints. 426 
Xenotransfusion is mainly used for short-term stabilisation of an anaemic cat, allowing time for 427 
investigations or to obtain compatible feline blood or time for endogenous erythropoiesis to correct 428 
the anaemia 65-68 with or without appropriate treatment. Typically, 30-50 mls of canine blood is 429 
administered using the same administration rates (see later) as feline blood.  430 
 431 
Antibodies to donor canine RBCs are detected 4-7 days following transfusion of canine blood into cats 432 
67, resulting in destruction of donor RBCs and a late haemolytic reaction and hence a shorter life span 433 
of the donor canine RBCs compared to the life span of appropriately typed feline RBCs (30 days 69). 434 
Subsequent repeat transfusion of canine blood to the cat will result in a severe transfusion reaction, 435 
anaphylaxis and likely death 65. Reported short-term complications following xenotransfusion are 436 
similar to cat to cat transfusions (allotransfusions), with minor febrile non-haemolytic transfusion 437 
reactions seen in 12% of cases 68. A severe acute anaphylactic transfusion reaction immediately upon 438 
administration of canine whole blood to a transfusion naïve cat has been reported (Korman, personal 439 
communication). Delayed haemolysis, often manifesting as icterus, occurs in 64% of cats at a median 440 
of 2 days (range of 1 to 6 days) after transfusion 68, meaning the benefits of xenotransfusion are short 441 
lived compared to allotransfusion. Pre-xenotransfusion cross-matching results do not appear to 442 
predict the development of transfusion reactions67, 68.  In one study 68 the long-term outcome of cats 443 
given xenotransfusions appeared to be associated with their primary disease and those that recovered 444 
appeared to have no notable adverse effects that could be directly attributed to xenotransfusion. 445 
 446 
Chemical restraint of the donor for blood transfusion  447 
It is possible to perform blood collection in conscious cats with a skilled veterinary care team; 448 
however, these patients must be cooperative and blood donation may be a negative experience for 449 
donors. Movement during donation and signs of anxiety have been reported in conscious cats much 450 
more often than in sedated cats 70. Additionally, stress produced by handling may affect the cellular 451 
and chemical composition of the blood (e.g. hyperglycaemia) 71. Therefore, chemical restraint or 452 
general anaesthesia is now commonly used for both in-clinic and client-owned feline donors. The 453 
choice of a short-term (30 minutes) protocol for chemical restraint will avoid an uncomfortable 454 
experience for the cat and failed, repeated interventions that could produce injuries to the 455 
veterinary care team. It will also influence owner satisfaction with the donor experience 72.  456 
Chemical restraint for feline blood donors is no different to any other anaesthetic procedure in the 457 
sense that preoperative examination and appropriate fasting (6 hours) are mandatory. An 458 
anaesthetic plan, including monitoring and careful choice of dosage regimens, is required. The use of 459 
local anaesthetic creams (see Figure 4) and pheromones may be part of the overall management of 460 
the patient to help reduce stress. 461 
 462 
The intravenous route of administration is often preferred due to the rapid onset of action and the 463 
use of lower doses of anaesthetic agents when compared with the intramuscular and subcutaneous 464 
routes. Several studies have reported the feasibility, and effects, of different drug combinations on 465 
major blood analytes in cat donors (see Table 2). Overall, each protocol has its unique advantages 466 
and disadvantages. Ideally, the drug combination should have a short onset with adequate depth 467 
and duration of action and include a smooth and rapid anaesthetic recovery with minimal 468 
cardiorespiratory depression on the donor. The choice will be also dependent on drug availability 469 
and the familiarity of the veterinary care team with the protocol. Eye lubricant should be applied to 470 
all cats regularly (every 10-15 minutes) to avoid eye ulcers and lesions. Ideally, the cat should return 471 
to its normal behaviour, and eat and drink, shortly after the end of anaesthesia. 472 
 473 
α2-adrenergic receptors agonists (xylazine, medetomidine and dexmedetomidine) are to be avoided 474 
for several reasons (see Table 2). Propofol produces significant cardiorespiratory depression and 475 
may lead to the formation of Heinz bodies, so is also best avoided. Ketamine is often used as part of 476 
drug protocols; however, it should not be administered alone since muscle jerks, hallucinogenic 477 
behaviour, hyperaesthesia and emergency delirium (growling, biting, scratching, lunging at the cage) 478 
have been observed. Sevoflurane has been used for feline blood donation since induction of, and 479 
recovery from, anaesthesia is rapid and predictable (Table 2).  480 
 481 
Table 2: Summary of different drug combinations that can be used in blood donors and their effect 482 
on major blood analytes. RBC: red blood cell; HCT: haematocrit; Hb: haemoglobin; WBC: white blood 483 
cells; PCV: packed cell volume, IV intravenous, IM intramuscular. 484 
Drugs Dose or dosage or 
inhalant concentration 
commonly reported 
Comments Changes in blood 





10 mg ketamine + 0.5 
mg diazepam, both IV 
Protocol for short-term 
venipuncture (5 minutes). 
Short onset and duration of 
action with excellent chemical 
restraint but may not be 
enough to complete 
phlebotomy. Note: diazepam 
should not be administered 
IM 
Minimal decreases in 
plasma triglycerides 
and albumin, and 









4-6 mg/kg ketamine + 
0.4 mg/kg midazolam, 
both IM 
Mixed in the same syringe for 
IM injection.  Prolonged 
anaesthetic effects, with 
ataxia and recumbency for up 
to 4-6 hours after 
phlebotomy. Alternative 
protocols include the addition 
Decreases around 24-
25% in RBC count, Hb 
concentrations and 
PCV after higher doses 
of ketamine (10 mg/kg) 
and midazolam (0.5 
mg/kg) IV. Based on 
74-76 
Drugs Dose or dosage or 
inhalant concentration 
commonly reported 
Comments Changes in blood 
analytes reported in 
studies 
References 
of butorphanol (0.3 mg/kg) or 
buprenorphine (0.01 mg/kg) 
IM. Hyperthermia may occur 
with ketamine-based 
protocols 
these PCV changes, 
some donors may be 





dexmedetomidine +  
0.2 mg/kg butorphanol, 
both IM 
Ease of administration with 
short onset of action and 
possibility of 
dexmedetomidine reversal 
with atipamezole (0.1 mg/kg 
IM). Good muscle relaxation. 
Adverse effects include 
emesis, bradycardia, 
increased systemic vascular 
resistance and decreases in 
cardiac output. Peripheral 
vasoconstriction poses an 
additional challenge to 
venous catheterization and 
blood collection; several 
donations were aborted due 
to this. Higher doses of 
dexmedetomidine might be 
required in some cats 
Decreases in RBC 
count, Hb 
concentration and HCT 
values (i.e. 
sequestration of 
erythrocytes by the 







2 mg/kg alfaxalone +  
0.2-0.4 mg/kg 
butorphanol, both IM 
Minimal cardiorespiratory 
changes. Large volume of IM 
injection. Rapid recovery from 
anaesthesia (just over 30 
minutes). Additional sedation 
or gentle physical restraint 
might be required in some 
cats; further administration of 
alfaxalone (0.1 mg/kg IV) can 
be used but will prolong 
duration and recovery of 
anaesthesia. In the author’s 
experience (PS), twitching can 
be observed 
No changes in 
complete blood count 
or serum biochemical 
values in experimental 
cats after doses of 5 
mg/kg and 15 mg/kg IV  
72, 78, 79 
Tiletamine and 
zolazepam 
2.5 mg/kg of each of 
tiletamine and 
zolazepam, both IM 
Short onset of action.  
Hypothermia can be 
observed. Increases in heart 
rate and blood pressure due 
to hypovolemia and drug-
induced sympathetic 
stimulation. 
RBC, HCT, Hb, WBC, 
platelet, neutrophil 
and monocyte counts 
decreased, and 
lymphocyte, eosinophil 
and basophil counts 




Sevoflurane Mask or “box” induction 
with sevoflurane (4-5% 
for induction followed by 
2-3% for maintenance 
using 2 L/min of oxygen) 
Potentially stressful to the 
cat. Anaesthesia is best 
induced by wrapping the cat 
in a towel with gentle 
restraint using a snug-fitting 
mask to the face. Possibility of 
Not reported 75 
Drugs Dose or dosage or 
inhalant concentration 
commonly reported 
Comments Changes in blood 
analytes reported in 
studies 
References 
profound agitation during 
recovery. Environmental 
exposure of the veterinary 
care team to the inhalant 
anaesthetic. Higher 
prevalence of hypotension 
when compared with 
ketamine combinations. An 
endotracheal tube should be 
available if intubation is 
required 
 485 
Monitoring of mucous membrane colour, temperature, pulse and respiration rate of the donor cat 486 
should be performed throughout the anaesthetic procedure and blood collection. Pulse oximetry 487 
(SpO2) can be used as a non-invasive method to determine the percentage of arterial haemoglobin 488 
saturated with oxygen. The device can be placed over the plantar digit of a pelvic limb during 489 
collection. Hypothermia is prevented by positioning the cat over a circulating warm water blanket or 490 
other warming device (with appropriate safety measures). Blood donation implies controlled losses 491 
of up to 20% (40-60 ml) of a cat’s blood volume over a short period of time. As hypotension (systolic 492 
< 80–90 mmHg, mean < 60–70 mmHg, and diastolic <40 mmHg) is commonly observed with both 493 
injectable and inhalant anaesthetic protocols 75, 81, blood pressure monitoring is recommended due 494 
to potential hypovolaemia and the effects of anaesthetics.  Depending on the donor protocol, 495 
balanced crystalloid solutions may be provided via intravenously or via the subcutaneous route 496 
immediately after donation. Arterial partial pressure of oxygen can decrease during chemical 497 
restraint and oxygenation via a tight facemask is recommended. Desaturation (SpO2 < 90%) indicates 498 
hypoxaemia and oxygenation must be administered in this case especially with protocols using a 499 
combination of opioid-dexmedetomidine-ketamine or alfaxalone 82. Other measures may be 500 
required including drug reversal and termination of the procedure. 501 
 502 
Practical blood collection  503 
The anticoagulant-preservative solutions most often used for collection of blood for transfusion 504 
purposes are ACD-A (anticoagulant citrate-dextrose solution), CPD (citrate-phosphate-dextrose) or 505 
CPDA-1 (citrate-phosphate-dextrose-adenine). The volume of anticoagulant used and the duration 506 
of time for which the blood product can be stored vary depending on the anticoagulant-preservative 507 
solution and the collection method. ACD-A, CPD and CPDA-1 typically are used in a ratio of 1 ml 508 
anticoagulant to 7ml of blood. Sodium citrate (3.2 or 3.8%) alone (without RBC preservatives) may 509 
be used at a ratio of 1 ml anticoagulant to 9 ml of blood if the blood is to be administered within 24 510 
hours of collection. Use of heparin as an anticoagulant for blood collected for transfusion is not 511 
recommended. 512 
 513 
Blood collection systems are described as “open” or “closed”. A closed system is one in which the 514 
only exposure of the collection bag or its contents to air prior to administration is when the needle is 515 
uncapped to perform venipuncture during collection. An open system is one in which there is one or 516 
more additional sites of potential bacterial contamination during blood collection or processing, with 517 
examples being the use of syringes or empty bags with added anticoagulant to collect blood, as 518 
frequently used in cats (Figure 5).  Blood products collected in an open system should be ideally 519 
administered within four hours, or if stored in a refrigerator (1-6°C) they should be administered 520 
within 24 hours.  521 
 522 
A commercially available feline closed collection system (Figure 6a and Figure 6b) has been 523 
evaluated for storage of feline blood for 35 days, with one of eight blood units showing bacterial 524 
growth (Serratia marcescens) on day 35 but not day zero 83, highlighting the fact that bacterial 525 
contamination of a blood unit during collection is an issue regardless of whether using an open or 526 
closed collection system. Another closed feline blood collection system was recently evaluated 527 
which permits blood collection by suction using a vacuum chamber, which accelerated the process 528 
without being detrimental to the blood donor, therefore optimizing collection 84. In addition, this 529 
study directly compared this closed system to an open system, for evidence of bacterial 530 
contamination, and did not observe any difference in bacterial contamination of the units between 531 
the two collection systems 84. Also, blood units and blood products collected using open systems 532 
have previously been stored successfully without microbial growth, although all blood banking was 533 
done by experienced staff and blood was collected with appropriate aseptic collection methods, 534 
processing and careful storage to prevent contamination 85, which may have contributed to this 535 
result. 536 
 537 
The volume of blood that may be collected safely from feline donors is approximately 20% of their 538 
blood volume (blood volume approximately 50-60 ml/kg) every four weeks; thus a recommended 539 
volume limit is approximately 10-12 ml/kg for cats based on lean body weight 81. For practical 540 
purposes, a routine feline blood collection is a total volume of approximately 40-60 ml, including 541 
anticoagulant. Most volunteer donor schemes using client-owned pets as donors extend the 542 
donation interval to every 8-12 weeks, and at this frequency supplementation with iron is not 543 
required unless a deficiency is detected. 544 
 545 
The jugular vein is the recommended venipuncture site in cats because of its size and accessibility. 546 
Strict aseptic technique minimizes the possibility of bacterial contamination (see text box for 547 
collection procedure). In a retrospective observational study of 115 feline blood donations (70 non-548 
sedated and 45 sedated), evidence of cardiovascular or respiratory distress was noted in three non-549 
sedated cats after donation; panting, tachypnoea, and collapse were each observed in one cat, all of 550 
which were determined to be normotensive within minutes of the untoward event 70 and recovered 551 
fully. Further study is required to assess the complication rate between sedated and non-sedated 552 
donors but, in most cats, sedation is preferred to reduce patient anxiety and potential movement 553 
and trauma to the jugular vein during donation. Assessment of patient demeanour should form part 554 
of the pre-donation assessment and examination.  555 
 556 
After blood collection and during recovery from chemical restraint donors should continue to be 557 
monitored as indicated above (mucous membrane colour, pulse and respiratory rate, and systolic 558 
blood pressure if indicated) and optionally provided subcutaneous or intravenous fluids. The patient 559 
may be discharged once vital parameters are in the normal range, and ideally after food is eaten, 560 
before discharge.  561 
 562 
BOX OUT START 563 
Fluid therapy for feline blood donors 564 
Provision of fluid therapy prior, during or after collection of blood from a donor varies between 565 
centres and clinicians. No detrimental effects are reported in large donor programs when crystalloid 566 
fluids are not supplemented (Penn Animal Blood Bank, personal communication) and other authors 567 
provide 90 ml lactated Ringer’s solution subcutaneously prior to collection of the donation, and the 568 
same solution is administered intravenously at 10 ml/kg starting halfway through the donation 86. 569 
Others supplement with a balanced crystalloid solution such as Hartmann’s or lactated Ringer’s 570 
solution at 2-3 times the volume of blood collected, given immediately intravenously after the 571 
donation is completed 87. 572 
BOX OUT END 573 
 574 
BOX OUT START 575 
Feline blood collection procedure using open system (equipment shown in Figure 5) 576 
1. A pre-donation blood sample can be collected from an intravenous catheter or peripheral 577 
vein for measurement of PCV or haemoglobin via a haemoglobin monitor. Perform the 578 
blood collection only if PCV or haemoglobin is in the reference interval. 579 
2. Syringes (several 10, 20, or one 60 ml) are pre-filled with an appropriate volume of 580 
anticoagulant (1 ml of ACD-A, CPD or CPDA-1 per 7 ml of blood to be collected). 581 
3. The donor is restrained in the position preferred by the phlebotomist e.g. a sitting position 582 
with head raised (especially if not sedated); if sedated, the cat can be placed in sternal 583 
recumbency with forelimbs over the edge of a table and the head raised (Figure 6a) or in 584 
lateral (Figure 6b and Figure 6c) or dorsal recumbency with the neck extended (Figure 6d). 585 
4. The hair over the jugular vein is clipped and the venipuncture site is prepared using an 586 
aseptic technique (Figure 6c).  587 
5. Pressure is applied at the thoracic inlet to raise the jugular vein, and a butterfly catheter (19 588 
or 21 gauge) is inserted into the jugular vein.  589 
6. The phlebotomist keeps the butterfly needle within the jugular vein as still as possible, 590 
whilst each syringe is filled in turn and gently rocked to ensure mixing of blood and 591 
anticoagulant during collection by an assistant. Sometimes occlusion of both jugular veins 592 
can accelerate blood collection if syringe filling flow has slowed down. 593 
7. After collection, the butterfly needle is removed from the jugular vein, and pressure is 594 
applied to the venipuncture site to prevent haematoma formation.   595 
If a blood clot is found in one syringe only, that syringe should be discarded if possible.  596 
A more detailed step-by-step photo guide of blood collection is available elsewhere 87 597 
BOX OUT END 598 
 599 
BOX OUT START  600 
Feline blood collection procedure using closed system (equipment shown in Figure 7) 601 
A TEC 724 blood collection kit for cats (Futurlab Srl, Limena, Padova, Italy) can be used for closed 602 
blood collection, as previously described 83, 88. Figure 7a and Figure 7b show the system set up with a 603 
description of its use below.  604 
1. Close clamp 3, leave clamps 1 and 2 open. 605 
2. Push the plunger of the 10 ml syringe ‘C’ up to the first thick black permanent marker line to put 606 
around 3 ml of anticoagulant into the system (on 1st occasion before the first withdrawal of blood 607 
from the donor make sure the anticoagulant solution reaches the break-valve ‘B’ to prevent 608 
subsequent coagulation in the collection line.  This means around 3 ml of anticoagulant will be in 609 
the closed collection system to go into the blood collection syringe ‘D’ alongside around 20 ml of 610 
blood aspirated from donor; this maintains the approximate correct 1:7 ratio of anticoagulant to 611 
blood).  612 
3. Close clamp 1. 613 
4. Remove the cap of the luer lock connection ‘A’ and connect it to the butterfly needle of the 614 
desired gauge to collect blood from the donor cat.  615 
5. Obtain donor jugular vein access with the butterfly needle, ensuring it is correctly inserted and 616 
then held still. 617 
6. Break the break-valve ‘B’ (this valve means that the donor blood is never in contact with the air, 618 
ensuring the system remains closed). 619 
7. Draw the 20ml of blood into the ‘D’ syringe via aspiration – the blood comes into contact with, 620 
and will mix with, the anticoagulant previously placed in the system.  621 
8. Once the ‘D’ syringe has been filled with blood mixed and anticoagulant, open clamp 3 and push 622 
the plunger of syringe ‘D’ so that the blood goes through the unidirectional valve ‘E’ into the 623 
primary bag ‘F’ (see Figure 7b). 624 
9. Close clamp 3, open clamp 1 and then repeat steps 2, 7 and 8. 625 
10. Repeat step 9 until collection of blood complete; the anticoagulant solution allows collection of 626 
up to 60 ml ± 10% of blood (primary bag capacity is 80 ml). 627 
11. When the blood collection is complete, close clamp 2 and remove the butterfly needle from the 628 
donor, applying pressure to the jugular vein.  629 
12. Separate the equipment at the point indicated by the black cross in Figure 6a by means of an 630 
electric or manual sealer (a sealer is a tool used to close off the blood bag by sealing the tube 631 
using heat or metal; used mainly in blood banks, but available for purchase, but metallic clamps 632 
can be used if not available) – this separates the blood-filled primary bag ‘F’ of blood (and the 633 
plasma satellite bag ‘I’) from the syringes and rest of the kit. 634 
13. To infuse the collected blood in ‘F’, connect the luer lock infusion adapter ‘K’ (provided with the 635 
kit) to the valve ‘G’ and remove the butterfly cap from the other end to connect with an infusion 636 
set with spike.  If not given to the recipient immediately, the collected blood can be stored at 4-637 
6°C. It is possible to take samples from the bag by connecting a luer lock syringe to the needle 638 
free valve ‘G’.   639 
14. Although very unlikely in general practice, as blood bank centrifuges are usually only available in 640 
blood banking organisations, the closed collection kit shown can also be used to divide the FWB 641 
collected into one packed red blood cell (pRBC) unit and one plasma unit. This is done by 642 
centrifugation of the primary and satellite bags in specialized blood bank centrifuges, then 643 
breakage of the break-valve ‘H’ and transfer of plasma to the bag ‘I’ which is then sealed at the 644 
position of the blue cross in Figure 7a. Plasma can then be stored frozen at -20°C for up to one 645 
year (as fresh frozen plasma - FFP) or from one to five years (as frozen plasma - FP). Samples from 646 
the plasma bag can be taken by connecting a luer lock syringe to the needle free valve ‘J’. The 647 
luer lock infusion adapter ‘K’ can be attached to the valve ‘J’ and connected to an infusion set 648 
with spike for administration. 649 
BOX OUT END 650 
         651 
While most cats in need of a transfusion in clinical practice receive FWB, the high erythrocyte 652 
sedimentation rate of feline blood allows for the separation of plasma and RBCs by simply placing 653 
blood-filled syringes upright for approximately one hour at room temperature 89 (Figure 8a). Plasma 654 
can then be expressed into a transfer pack and frozen within 8 hours of collection, if not 655 
immediately needed (Figure 8b). Packed RBCs can then be administered directly from the syringe or 656 
expressed into a transfer pack containing 10 ml of an additive solution, such as SAGM - saline, 657 
adenine, glucose, and mannitol, and stored in a refrigerator 90. This is could useful when feline blood 658 
components are not readily available from a commercial blood blank.  659 
 660 
Practical blood administration  661 
Blood products are usually given intravenously via a peripheral vein, but occasionally via a central 662 
vein or via an intraosseous route in small patients. A dedicated intravenous line should be used. 663 
 664 
Blood products should not be administered with intravenous fluids containing calcium or glucose 665 
supplementation (e.g. Hartmann’s, lactated Ringer’s). Calcium overwhelms the chelating ability of 666 
the citrate anticoagulant in stored blood and increases risk of clot formation. Appropriate fluid 667 
choices would be 0.9% saline or Plasmalyte.   668 
 669 
Blood products must be administered using an appropriate filter to reduce red cell aggregates and 670 
microthrombi entering the recipient’s circulation. Filters in standard fluid therapy administration 671 
sets are too small and blood will clot if administered through them. Use of a syringe and 672 
microaggregate filter system does not appear to damage transfused RBCs 91. Gravity administration 673 
using a standard blood giving set can be used but control of administration rate is more difficult. 674 
Ideally, a syringe and syringe driver with an inline microaggregate filter system (e.g. Hemo-Nate 18 675 
μm filter, IMS, UK) is best. In most centres the filter is placed in the administration line as close to 676 
the patient as possible (Figure 9). Some authors will filter the blood as it is removed from the bag 677 
into a syringe, prior to administration to the patient. Either is an appropriate method for removing 678 
microthrombi from the FWB or pRBCs. 679 
 680 
Transfusion volume and rate  681 
The volume of blood product administered to a patient can be calculated with various formulae, 682 
with the following formula performing best in one study, although formulas frequently fail to 683 
accurately predict post-transfusion recipient PCV 92. 684 
PCV% increase = volume of blood transfused in ml/ (2 x bodyweight in kg) 685 
Practically, administration volume is rounded to the nearest unit (40-60 ml whole blood) unless the 686 
recipient is very small in which case a half unit or 10 ml/kg may be administered.  687 
 688 
The rate of administration of the transfusion is determined by the condition of the patient. Patients 689 
with severe clinical signs associated with anaemia (e.g. weakness, tachycardia, tachypnoea, 690 
hyperdynamic or weak pulses, hypotension, dull mentation) may require blood products faster i.e. 691 
as a bolus or over 1-2 hours. Alternatively, as cats with severe or chronic anaemia may have signs of 692 
left heart overload 93, transfusions may need to be given over a longer period (e.g. 4-6 hours) to 693 
reduce the risk of transfusion associated circulatory overload. However, recent work described a 694 
lack of transfusion-associated circulatory overload in anaemic cats and dogs receiving transfusions 695 
94, suggesting that such an adjustment may not be required routinely, although it is still a risk in 696 
patients with underlying cardiac disease, for example, and so close monitoring is indicated. If blood 697 
products are kept at room temperature for more than 4 hours there is a greater risk of bacterial 698 
contamination, which should also be considered when calculating administration rates.  699 
 700 
BOX OUT START 701 
Rate of transfusion administration  702 
In patients not requiring rapid volume replacement, transfused blood should be administered at 0.5 703 
ml/kg/hour for the first 30 minutes and the patient monitored constantly for signs of a transfusion 704 
reaction (see below) such as vocalization, tachycardia, hypersalivation, vomiting, diarrhoea, facial 705 
swelling/urticaria, piloerection, or tachypnoea/respiratory distress. After this time, the rate may be 706 
increased to 1 ml/kg/hr for 30 minutes. If there is still no evidence of a transfusion reaction, the 707 
administration rate is increased so the total transfusion volume remaining is administered within a 708 
4-hour period, although some follow the 1 ml/kg/hr rate with a period of 20 minutes at 2 ml/kg/hr 709 
before increasing the rate further. 710 
BOX OUT END 711 
 712 
Monitoring the recipient 713 
Patients must be monitored very closely whenever receiving a blood transfusion, particularly within 714 
the first 30 minutes of administration as this is the most common time for a severe transfusion 715 
reaction to develop.  A baseline check of vital signs is performed before commencing the 716 
transfusion, including temperature, heart rate, pulse quality, blood pressure, mucous membrane 717 
colour, respiratory rate/effort, oxygen saturation and patient mentation.  718 
 719 
These parameters are checked very frequently (initially every five minutes) for the first 30-60 720 
minutes (Figure 10a and Figure 10b). Depending on the clinical status of the patient, a 721 
multiparameter machine may be used to allow continuous monitoring of heart rate, 722 
electrocardiogram, SpO2, blood pressure and temperature throughout the transfusion. Assessment 723 
of vital parameter data trends (e.g. gradual increase in heart rate, respiratory rate, temperature) is 724 
key to early identification of a transfusion reaction and ensuring detailed records are kept 725 
throughout the transfusion is extremely important (Table 3). 726 
 727 
Table 3: An example of a blood product administration sheet used for monitoring cats to help allow 728 
for early detection of any problems. T = temperature. P = pulse rate. R = respiration rate. BP = blood 729 
pressure. MMemb = mucous membrane. PCV = packed cell volume.  730 
Example Blood Product Administration Sheet for Cats 731 
               Date ………………………….….…… 732 
Weight ………  kg    Vet ………….   733 
Blood type …………………………. 734 
Donor reference ………………….. 735 
Cross-matched? Y □ N □ 736 
Blood product (likely whole blood) 737 
………………………………………… Unit size ………………… mls 738 
Dose estimation:  ≈1% increase in PCV is seen for every 2ml/kg of whole blood 739 







0.5 ml/kg/hr  
for 1st 30 mins  
Volume = ………ml/hr 
T, P, R, BP 
Q 15 mins for 
1st hour & then 







1.0 ml/kg/hr  
for next 30 mins 




As prescribed – 
but should not 
really exceed  
10 ml/kg/hr 
Remainder of unit volume 
given over 4 hours  
Volume =  
 
………ml/hr 
Complete the transfusion within 4 hours 740 













Start         
15mins         
30mins         
45mins         




        
        
End          
 741 
Patient Sticker 
Total volume given (mls)     _______________________ 742 




Please record any notes and further checks on the patient’s sheet 747 
Signs of a transfusion reaction include pyrexia, restlessness, vomiting, salivation, change in 748 
RR and/or pattern (dyspnoea), change in HR and/or rhythm, change in BP, weak pulses, 749 
vocalization, diarrhoea, urticaria.  750 
If any reaction is seen, the transfusion should be stopped immediately, and the vet 751 
contacted. The volume infused, and rate of infusion is recorded (do not discard the blood, 752 
line or fluids).  Other considerations may be required under vet guidance: 753 
▪ Start cardiopulmonary resuscitation (CPR) if necessary  754 
▪ Examine the unit for haemolysis by spinning a microhaematocrit tube containing a 755 
sample of the donor blood and look for haemoglobinaemia 756 
▪ Examine the recipient for haemolysis by spinning a microhaematocrit tube of blood from 757 
the recipient and look for haemoglobinaemia 758 
▪ Consider starting IVF therapy (e.g. crystalloid bolus at 10 ml/kg) – this may be required 759 
to avoid renal damage if severe intravascular haemolysis or if signs of shock are present  760 
(hypotension, pallor, tachycardia/bradycardia) 761 
▪ Consider treatment with adrenaline (10-20 g/kg of a 1: 10,000 solution (100 g (0.1 mg) 762 
per ml) IV or IM) and antihistamines (e.g. diphenhydramine 1 mg/kg IV or IM)  763 
▪ If volume overload has resulted in pulmonary oedema, diuretic treatment and oxygen 764 
support may be required – chest imaging and/or echocardiography may be indicated 765 
▪ Culture (or e.g. PCR) of a sample of the donor unit may be required if infection or 766 
contamination is suspected, but bacterial contamination is unlikely in fresh well-handled 767 
blood 768 
▪ Antipyretics (e.g. meloxicam) may be required in some cases (renal function must be ok)  769 
Transfusion Reactions  770 
Despite appropriate screening, transfusion reactions in cats remain unpredictable and can vary in 771 
severity. Transfusion reactions can be defined as acute or delayed (see Table 4). The most common 772 
transfusion reactions seen in cats include febrile non-haemolytic transfusion reactions, allergic 773 
reactions and transfusion-associated circulatory overload. Transfusion reactions may cause immune-774 
mediated haemolysis, which can result in jaundice, pigmenturia and/or pyrexia, mainly due to anti-775 
blood type reactions. Transfusion reactions can also cause non-haemolytic reactions e.g. transient 776 
increases in body temperature, facial pruritis, facial swelling (Figure 11), vomiting and salivation. 777 
Increased vocalisation or agitation can often be a preceding sign to a non-haemolytic reaction. 778 
 779 
Table 4: Association of Veterinary Haematology and Transfusion Medicine (AVHTM) Consensus 780 
Working Group definitions of transfusion reactions (reproduced with permission from AVHTM 95).  781 




Acute, non-infectious, immunologic, or non-immunologic reaction that 
occurs secondary to accelerated destruction of transfused or recipient 
RBCs and is characterized by acute haemolysis. Acute haemolytic 
transfusion reactions occur during or within 24 hours of blood product 
administration. Causes of AHTRs can be divided into blood type 
incompatibilities and other causes of damage to transfused blood cells. 
Blood type incompatibilities are immunologic acute haemolytic reactions 
that are type II hypersensitivity reactions due to major or minor 
incompatibilities between donor and recipient RBCs. A classic example 
would be in the case of a type A unit of blood given to a type B cat. Non-
immunologic causes of AHTRs may include thermal, osmotic, mechanical, 
or chemical factors that damage transfused blood cells. 
Allergic Reaction  
Acute immunologic reaction that is secondary to a type I hypersensitivity 
response to an antigen within a blood product. This reaction occurs during 
or within 4 hours of transfusion.  It is characterized by clinical signs varying 
from transient and self-limiting to life-threatening anaphylaxis.  Feline type 
I hypersensitivity reactions are typically respiratory (due to upper 
respiratory tract oedema, bronchoconstriction, and excessive mucus 
production) although gastrointestinal signs and severe pruritus can also 





Acute non-immunologic or immunologic reaction characterized by a 
temperature > 39°C (102.5°F) AND an increase in temperature of > 1°C 
(1.8°F) from the pre-transfusion body temperature during or within 4 
hours of the end of a transfusion where external warming, underlying 





Acute, non-immunologic reaction that is secondary to an increase in blood 
volume mediated by blood transfusion, characterized by acute respiratory 
distress and hydrostatic pulmonary oedema.  This reaction occurs during 
or within 6 hours of transfusion. It is associated with clinical, 
echocardiographic, radiographic, or laboratory evidence of left atrial 
hypertension or volume overload.  These patients typically have a positive 




Acute, immunologic reaction that is secondary to antigen-antibody 
interactions in the lungs. TRALI is characterized by acute hypoxemia with 
evidence of non-cardiogenic pulmonary oedema on thoracic radiographs, 
during or within six hours of allogenic blood transfusion. Patients 
diagnosed with TRALI have no prior lung injury, no evidence of left atrial 





Acute transfusion reaction characterized by the development of acute 
respiratory distress during or within 24 hours of the end of a transfusion 
where TACO, TRALI, allergic reaction, and underlying pulmonary disease 




Acute, non-immunologic reaction that is secondary to the infusion of 
stimulators of vasodilation and hypotension. It is characterized by the 
rapid onset of significant hypotension during or shortly after the 
completion of a transfusion, with the absence of other causes of 
hypotension, and improvement with cessation of the infusion. There is 




Acute, non-immunologic reaction that is secondary to the transfusion of a 
large volume of blood, with citrate as the anticoagulant, and is 




Acute, non-immunologic reaction that is secondary to hyperammonaemia 
and characterized by signs of development of encephalopathy (neurologic 
signs as ataxia, head pressing, circling, seizures and vomiting), during or 
immediately after (minutes to few hours) blood transfusion of stored 
blood or stored blood components.  It is a potentially life-threatening 
reaction in patients with liver disease (liver failure, portosystemic shunt, 
premature neonates with immature functioning liver) who are unable to 
metabolize and excrete ammonia properly.  




Acute or delayed, non-immunologic reaction secondary to the transfusion 
of pathogen contaminated blood or blood components. A TTI can occur 
hours to years after the transfusion due to the presence of the infectious 
agent in the blood/blood component unit collected from an infected 
donor, or from pathogen contamination of blood/blood component units 
during processing, storage or transfusion. Clinical signs are highly 
dependent on pathogen transmitted and its pathogenicity for dogs and 
cats and the clinical status of the recipient.  
Transfusion-
associated graft vs. 
host disease 
(TAGVHD) 
Acute to delayed immunologic reaction that is secondary to donor 
lymphocytes engrafting on and eventually attacking host tissue. TAGVHD 
occurs 48 hours to 6 weeks following transfusion and has a high mortality 
rate in human patients (>90%). The reaction is characterized by a skin rash, 
diarrhea, fever, hepatic dysfunction, and bone marrow hypoplasia. Liver 
and skin histopathology have a characteristic appearance. In humans, it is 
most common in immunocompromised individuals or when special 
circumstances cause transient immunosuppression. 





Delayed, non-infectious, immunologic or non-immunologic, reaction that 
occurs secondary to lysis or accelerated clearance of transfused RBCs. 
Delayed haemolytic transfusion reactions occur 24 hours to 28 days after 
blood product administration. Immunologic DHTRs are typically caused 
by a secondary immune response to the donor’s RBCs.  Non-immunologic 
HTRs occur due to thermal, osmotic, mechanical, or chemical factors that 




Delayed, immunologic reaction that is secondary to the development of 
new clinically significant antibodies against the transfused product without 
evidence of haemolysis.  DSTRs occur 24 hours to 28 days after a 




Delayed, immunologic reaction that is secondary to alloimmunization 
against platelet antigens. It is characterized by thrombocytopenia arising 
5-12 days following transfusion of any platelet-containing blood product. 
 782 
In a group of 126 cats receiving blood transfusions, non-haemolytic reactions (7.9%) were more 783 
common than haemolytic reactions (0.8%) 96. In another study of 91 cats, a transfusion reaction was 784 
only noted in 1.2% 57.  785 
 786 
The risk of a transfusion reaction increases with subsequent transfusions (typically from 2 days after 787 
an initial transfusion) 24. Appropriate record keeping is essential so that subsequent veterinarians are 788 
aware that the patient has received a blood transfusion. However, in 27 cats that received multiple 789 
blood transfusions, transfusion reactions remained uncommon 97.  790 
 791 
Should the patient develop mild signs of a transfusion reaction (e.g. mild 1-2◦C increase in 792 
temperature or one episode of vomiting) then the transfusion rate should be reduced. If marked 793 
clinical signs develop the transfusion should be stopped and blood replaced with a crystalloid 794 
solution. Monitoring of the patient should be continued for evidence of shock (temperature, pulse 795 
rate, mucous membrane colour and systolic blood pressure). Serum and urine should be assessed 796 
for haemolysis and haemoglobinuria with sample centrifugation (Table 3) to look for evidence of 797 
haemolysis of the transfused red cells (e.g. red discolouration of serum or urine).  798 
 799 
In the event of a severe transfusion reaction, the transfusion should be discontinued, and the 800 
patient assessed.  If signs of shock (hypotension, pallor, tachycardia/bradycardia) a crystalloid fluid 801 
bolus (10 ml/kg) and adrenaline (10-20 g/kg of a 1: 10,000 solution (100 g (0.1 mg) per ml) IV or 802 
IM) should be administered and can be followed by a continuous rate infusion (CRI) of adrenaline.  803 
Antihistamines (e.g. diphenhydramine 1 mg/kg IV or IM) and corticosteroids (e.g. hydrocortisone 2-804 
4mg/kg IV or IM or dexamethasone 0.05-0.1mg/kg IM or IV) may also be considered, although 805 
evidence for use of corticosteroids in acute transfusion reactions is limited and patient 806 
contraindications and potential adverse effects should be taken into account.  The donor blood 807 
sample/unit should be assessed by checking a PCV for evidence of haemolysis and potentially 808 
submitting a sample for bacterial culture. 809 
 810 
Cats may develop signs of volume overload following transfusion. This is of particular concern in 811 
patients with cardiac disease, normovolaemic to hypervolaemic anaemic patients (e.g. immune-812 
mediated haemolytic anaemia), and chronically or severely anaemic patients although, as 813 
mentioned above, this alone may be less of a clinical concern 94. If patients become tachypnoeic 814 
following a transfusion, or develop a serous nasal discharge or conjunctival oedema, thoracic 815 
radiographs or thoracic ultrasound should be performed to evaluate for pleural effusion or 816 
pulmonary oedema. If pleural effusion is present, thoracocentesis should be performed. If 817 
pulmonary oedema is present, furosemide 1-2mg/kg IV every two hours as required (based on 818 
respiratory auscultation, respiratory rate and response) and oxygen therapy should also be 819 
instigated.  820 
 821 
Autologous blood transfusion 822 
Autologous blood transfusion (autotransfusion) is the administration of a patient’s own blood as a 823 
transfusion. This can be considered in patients with haemothorax or haemoperitoneum. Cross-824 
matching or blood typing is not required. Blood is collected in a sterile fashion using a 23G butterfly 825 
needle and 10 or 20 ml syringes. Administration of the collected blood is otherwise similar to 826 
standard donor-recipient transfusions. There is no clear evidence regarding whether anticoagulant 827 
should be added to the transfusion. Blood in contact with the peritoneal surface is reported to 828 
become defibrinated within one hour and anticoagulant administration may be unnecessary or lead 829 
to hypocalcaemia. The use of a blood filter (18 μm) is strongly recommended to prevent platelet and 830 
leukocyte passage.  A recent report of eight cats with haemoperitoneum receiving autologous 831 
transfusion did not identify any adverse reactions 98.  832 
 833 
Conclusion  834 
Feline blood donation and transfusion can be performed safely and effectively in veterinary practice, 835 
but the decision to do so must be made carefully. Donor and recipient cats should be blood typed, 836 
and ideally cross-matched if possible, prior to transfusion to avoid severe transfusion reactions. The 837 
decision to administer a transfusion is based on the potential recipient’s clinical condition and cause 838 
of anaemia rather than PCV alone. Donors should be assessed for health, temperament and 839 
infectious agents and, in most cases, sedated appropriately for blood collection. Blood can be 840 
collected using an open or closed system and recipients should be monitored for signs of a 841 
transfusion reaction. Xenotransfusion may be given only once, allowing for short-term stabilisation 842 
of the recipient but destruction of donated RBCs occurs after a short time.  843 
 844 
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